- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.02. | Intensity Therapeutics announces 1-for-25 reverse stock split | 21 | Investing.com | ||
| INTENSITY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.02. | Intensity Therapeutics kündigt Aktienzusammenlegung im Verhältnis 1:25 an | 4 | Investing.com Deutsch | ||
| 13.02. | Intensity Therapeutics Inc.: Intensity Therapeutics Announces Reverse Stock Split | 199 | PR Newswire | Intensity's common stock is expected to begin trading on a post-split adjusted basis on February 19, 2026
SHELTON, Conn., Feb. 13, 2026 /PRNewswire/ -- Intensity... ► Artikel lesen | |
| 23.01. | INTENSITY THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 13.01. | Intensity Therapeutics legt nach klinischer Validierung Strategie für 2026 fest | 6 | Investing.com Deutsch | ||
| 13.01. | Intensity Therapeutics Inc.: Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities | 238 | PR Newswire | Peer-reviewed clinical validation, strengthened balance sheet, and disciplined execution position the Company for 2026
SHELTON, Conn., Jan. 13, 2026 /PRNewswire/... ► Artikel lesen | |
| 05.12.25 | Intensity Therapeutics receives 180-day Nasdaq extension to regain compliance | 13 | Seeking Alpha | ||
| 05.12.25 | Intensity Therapeutics gets 180-day extension to meet Nasdaq price rule | 1 | Investing.com | ||
| 04.12.25 | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.11.25 | Intensity Therapeutics GAAP EPS of -$0.06 in-line | 8 | Seeking Alpha | ||
| 06.11.25 | Intensity Therapeutics Inc.: Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 154 | PR Newswire | The Company expects to file a protocol amendment in the INVINCIBLE-4 Study to revise the dosing regimen for the INT230-6 treatment cohort, and to reinitiate... ► Artikel lesen | |
| 06.11.25 | INTENSITY THERAPEUTICS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 31.10.25 | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 31.10.25 | Intensity Therapeutics announces pricing of $4M registered direct offering of common stock | 11 | Seeking Alpha | ||
| 31.10.25 | Kapitalerhöhung mit hohem Abschlag: Aktie von Intensity Therapeutics stürzt ab | 16 | Investing.com Deutsch | ||
| 31.10.25 | Intensity Therapeutics stock tumbles after pricing $4 million offering | 3 | Investing.com | ||
| 31.10.25 | Intensity Therapeutics sichert sich 4 Millionen US-Dollar durch registrierte Direktplatzierung | 12 | Investing.com Deutsch | ||
| 31.10.25 | Intensity Therapeutics prices $4 million registered direct offering | 1 | Investing.com | ||
| 31.10.25 | Intensity Therapeutics Stock Cools After-Hours Following 395% Surge: What You Should Know | 14 | Benzinga.com | ||
| 30.10.25 | Intensity Therapeutics stock soars after phase 1/2 data publication | 10 | Investing.com |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 93,15 | -0,16 % | BioNTech, Valneva oder BB Biotech: Warum es HIER in Kürze knallt! | Die Biotechbranche steht zu Beginn des Jahres 2026 erneut im Spannungsfeld zwischen wissenschaftlicher Innovation und wachsender Skepsis der Kapitalmärkte. Nach Jahren extremer Kursbewegungen prüfen... ► Artikel lesen | |
| NOVAVAX | 8,361 | -2,53 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 48,800 | -4,31 % | Crispr Therapeutics gains amid takeover speculation | ||
| GINKGO BIOWORKS | 5,350 | -6,14 % | Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business | Ginkgo provides an update on its fourth quarter financial results
BOSTON, Feb. 26, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 3,188 | -3,06 % | Iovance Biotherapeutics, Inc.: Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas | 50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE... ► Artikel lesen | |
| NOVOCURE | 11,780 | +1,99 % | Novocure to Participate in 2026 Leerink Global Healthcare Conference | Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 10, 2026. Frank Leonard, Chief Executive Officer, and Christoph... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,009 | -30,77 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| MACROGENICS | 1,654 | -1,55 % | Weekly Buzz: MGNX's LINNET Trial On Hold; Eton Pharmaceuticals, ALUR Get FDA Nod; GILD Snaps Up ACLX | FOSTER CITY (dpa-AFX) - This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results... ► Artikel lesen | |
| SPERO THERAPEUTICS | 1,868 | +1,41 % | Anterix Inc.: Anterix Appoints Ross Spero as Chief Product Officer | WOODLAND PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Anterix, Inc. (NASDAQ: ATEX) today announced the appointment of Ross Spero as Chief Product Officer. Spero will lead Anterix's product development... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 17,510 | 0,00 % | MoonLake Immunotherapeutics - 10-K, Annual Report | ||
| X4 PHARMACEUTICALS | 2,450 | -100,00 % | X4 Pharmaceuticals, Inc.: X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome | - Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives... ► Artikel lesen | |
| KORRO BIO | 11,810 | -2,24 % | Clear Street upgrades Korro Bio stock rating on hyperammonemia program potential | ||
| NEUMORA THERAPEUTICS | 3,495 | -1,27 % | Neumora Therapeutics, Inc.: Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones | Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans to... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 62,98 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights | Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS... ► Artikel lesen |
Das Unternehmen INTENSITY THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,56 % bei einem Aktienkurs von 7,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTENSITY THERAPEUTICS INC finden Sie auf Wallstreet Online.